CompanyGraph
Carsgen Therapeutics Holdings Limited
2171 · HKEX · China
Price data from its CRTHF listing on OTC, quoted in USD
carsgen.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $20.39M, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.59BHKD1.22B · vs all stocks (USD)
Revenue (TTM)
159.99MHKD20.39M · vs all stocks (USD)
Profit Margin
-65.28%vs Biotechnology peers
Beta
0.2210xvs all stocks
52-Week Change
-37.13%vs all stocks
Market Capitalization
9.59BHKD1.22B · vs all stocks (USD)
Enterprise Value
6.85BHKD873.18M · vs all stocks (USD)
Forward P/E
5.56xvs Biotechnology peers
Price to Sales (TTM)
53.18xvs Biotechnology peers
Price to Book (MRQ)
5.58xvs Biotechnology peers
Enterprise to Revenue
42.82xvs Biotechnology peers
Enterprise to EBITDA
-26.96xvs Biotechnology peers
Profit Margin
-65.28%vs Biotechnology peers
Operating Margin
-215.69%vs Biotechnology peers
Return on Assets (TTM)
-8.91%vs Biotechnology peers
Return on Equity (TTM)
-9.56%vs Biotechnology peers
Revenue (TTM)
159.99MHKD20.39M · vs all stocks (USD)
Revenue per Share (TTM)
0.2470HKDUpdated Sep 20, 2026Quarterly Revenue Growth
21.50%vs Biotechnology peers
Gross Profit (TTM)
108.44MHKD13.82M · vs all stocks (USD)
EBITDA (TTM)
-254.11MHKD-32.39M · vs all stocks (USD)
Net Income (TTM)
-104.44MHKD-13.31M · vs all stocks (USD)
Operating Cash Flow (TTM)
-199.78MHKD-25.47M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-25.11MHKD-3.20M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-3.98MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1800CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
552.06MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
552.06MSharesFY2025 · Dec 31, 2025Operating Cash Flow
-114.48MCNYFY2025 · Dec 31, 2025Free Cash Flow
-119.61MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.12BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-102.91MCNYFY2025 · Dec 31, 2025Stock-based Compensation
25.28MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-9.90MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
219.00KCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-27.18MCNYFY2025 · Dec 31, 2025Capital Expenditures
-5.13MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.00MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.66BCNYFY2025 · Dec 31, 2025Sale of Investments
1.66BCNYFY2025 · Dec 31, 2025Other Investing Activity
600.00KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-4.78MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00CNYFY2025 · Dec 31, 2025Long-term Debt Payments
-89.00MCNYFY2025 · Dec 31, 2025Common Stock Repurchase
-115.28MCNYFY2025 · Dec 31, 2025Other Financing Charges
80.00MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-95.23MCNYFY2025 · Dec 31, 2025Shares Outstanding
546.16MSharesUpdated Sep 20, 2026Float Shares
353.97MSharesUpdated Sep 20, 2026% Held by Insiders
36.68%vs all stocks
% Held by Institutions
6.16%vs all stocks
Total Cash (MRQ)
1.64BHKD208.95M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.48HKDUpdated Sep 20, 2026Total Debt (MRQ)
84.30MHKD10.75M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0659xvs Biotechnology peers
Current Ratio (MRQ)
7.07xvs Biotechnology peers
Book Value per Share (MRQ)
2.28HKDUpdated Sep 20, 2026Total Assets
1.29BCNY192.81M · vs all stocks (USD)
Total Current Assets
1.18BCNYFY2025 · Dec 31, 2025Total Liabilities
512.80MCNYFY2025 · Dec 31, 2025Total Non-current Assets
114.05MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
307.34MCNYFY2025 · Dec 31, 2025Total Current Liabilities
205.46MCNYFY2025 · Dec 31, 2025Cash
1.11BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.11BCNYFY2025 · Dec 31, 2025Accounts Receivable
15.55MCNYFY2025 · Dec 31, 2025Inventory
7.14MCNYFY2025 · Dec 31, 2025Short-term Debt
12.84MCNYFY2025 · Dec 31, 2025Long-term Debt
48.34MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.00KCNYFY2025 · Dec 31, 2025Retained Earnings
-9.09BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
779.34MCNY116.29M · vs all stocks (USD)
Treasury Stock
0.00CNYFY2025 · Dec 31, 202552-Week Low
10.87HKDUpdated Sep 20, 202652-Week High
28.60HKDUpdated Sep 20, 202652-Week Change
-37.13%vs all stocks
Beta
0.2210xvs all stocks
50-Day MA
14.01HKDUpdated Sep 20, 2026200-Day MA
16.11HKDUpdated Sep 20, 2026Avg 10-Day Volume
2.30MSharesUpdated Sep 20, 2026Avg 30-Day Volume
2.54MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-0.2000HKDUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $20.39M, lower than 95% of all stocks globallySignificant
Revenue (USD): 20,393,604.585Global P5: 33,357,653.812
Market cap is $1.22B, above the global median of $1.18BNotable
Market cap (USD): 1,222,691,212.209Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Shandong Lukang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aurisco Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Cronos Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Harrow Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kissei Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sonoscape Medical Corp.
Tier 1ProductionApproval-Gated PipelineRule
LB Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai MicroPort EP MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Sun-Novo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Celltrion Pharm, Inc.
Tier 1ProductionApproval-Gated PipelineRule